Zeljko M Prijovic

Title: Zeljko M Prijovic: Innovator in Anti-Cancer Prodrugs

Introduction

Zeljko M Prijovic is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer treatment through his innovative work on anti-cancer prodrugs. His research focuses on enhancing the efficacy and safety of cancer therapies.

Latest Patents

Zeljko M Prijovic holds a patent for BQC-G, a tumor-selective anti-cancer prodrug. This invention relates to the synthesis of a second-generation camptothecin glucuronide prodrug derived from a potent anticancer camptothecin derivative known as 5,6-dihydro-4H-benzo[de]quinoline-camptothecin (BQC). BQC-G is over 4000 times more water-soluble than BQC and demonstrates good stability in human plasma. It serves as an excellent substrate for enzymatic hydrolysis by bacterial and human β-glucuronidases. Notably, BQC-G is about 30 times less toxic than BQC, but its toxicity increases after hydrolysis of the glucuronide moiety by β-glucuronidase. In the presence of human serum albumin, BQC-G shows lower cytotoxicity (IC=1080 nM) but can be activated by β-glucuronidase to exhibit potent activity (IC=13.3 nM).

Career Highlights

Zeljko M Prijovic is affiliated with Academia Sinica, where he conducts his research. His work has garnered attention for its potential to improve cancer treatment outcomes. He has successfully developed a prodrug that addresses the solubility and toxicity issues associated with traditional cancer therapies.

Collaborations

Zeljko has collaborated with notable colleagues, including Yu-Lin Leu and Steve R Roffler. Their combined expertise has contributed to the advancement of research in the field of anti-cancer drugs.

Conclusion

Zeljko M Prijovic's innovative work on BQC-G represents a significant advancement in the development of safer and more effective cancer treatments. His contributions to the field continue to inspire further research and development in anti-cancer therapies.